Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements Towards New Perspectives

Journal of Oncology - United States
doi 10.1155/2019/9513701
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Hindawi Limited

Related search

Retreatment With Nivolumab in Patients With R/R Classical Hodgkin Lymphoma After Discontinuation of the Therapy With Immune Checkpoint Inhibitors

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Lymphocyte-Rich Classical Hodgkin Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2018English

Circulating Dendritic Cells Deficiencies as a New Biomarker in Classical Hodgkin Lymphoma

British Journal of Haematology
Hematology
2018English

An Anaplastic T-Cell Lymphoma Mimicking Classical Hodgkin Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

Immune Checkpoint Inhibition: From Molecules to Clinical Application

Clinical and Experimental Immunology
AllergyImmunology
2020English

Hemophagocytic Lymphohistiocytosis in a Patient With Classical Hodgkin Lymphoma

Case Reports in Hematology
2016English

Novel Therapeutic Agents for Relapsed Classical Hodgkin Lymphoma

British Journal of Haematology
Hematology
2018English

EBV-Positive Plasmablastic Lymphoma Mimicking Reactive Lymphadenopathy Versus Recurrent Hodgkin Lymphoma Following Chemotherapy for Stage II Classical Hodgkin Lymphoma

Journal of Tumour Research & Reports
2018English

Chemotherapy and Radiation Improve Survival in Early Stage Classical Hodgkin Lymphoma: A Statewide Cancer Registry Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy